These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 15993950)

  • 41. Enhancement of anti-tumor immunity by high levels of Th1 and Th17 with a combination of dendritic cell fusion hybrids and regulatory T cell depletion in pancreatic cancer.
    Yamamoto M; Kamigaki T; Yamashita K; Hori Y; Hasegawa H; Kuroda D; Moriyama H; Nagata M; Ku Y; Kuroda Y
    Oncol Rep; 2009 Aug; 22(2):337-43. PubMed ID: 19578774
    [TBL] [Abstract][Full Text] [Related]  

  • 42. HER-2/neu-gene engineered dendritic cell vaccine stimulates stronger HER-2/neu-specific immune responses compared to DNA vaccination.
    Chan T; Sami A; El-Gayed A; Guo X; Xiang J
    Gene Ther; 2006 Oct; 13(19):1391-402. PubMed ID: 16724093
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cell fusion: from hybridoma to dendritic cell-based vaccine.
    Gong J; Koido S; Calderwood SK
    Expert Rev Vaccines; 2008 Sep; 7(7):1055-68. PubMed ID: 18767954
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [The cytotoxicity of CIK/NK cells stimulated by K562-DC fusion vaccines in NOD/SCID mice model for human erythroleukemia].
    Li Y; Huang SL; Zhang XC; Fang JP; Wu YF; Wei J; Huang WG; Zhou DH; Huang K; Lin YC
    Zhonghua Xue Ye Xue Za Zhi; 2008 Jan; 29(1):39-43. PubMed ID: 18512314
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Enhanced induction of anti-tumor immunity in human and mouse by dendritic cells pulsed with recombinant TAT fused human survivin protein.
    Cho HI; Kim EK; Park SY; Lee SK; Hong YK; Kim TG
    Cancer Lett; 2007 Dec; 258(2):189-98. PubMed ID: 17931768
    [TBL] [Abstract][Full Text] [Related]  

  • 46. B cell tumor vaccine enhanced by covalent attachment of immunoglobulin to surface proteins on dendritic cells.
    Lou Q; Conway TF; Egilmez NK; Loyall JL; Bernstein SH; Kelleher RJ; Bankert RB
    Clin Immunol; 2006 Jan; 118(1):66-76. PubMed ID: 16185929
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Tumor cell lysate-pulsed dendritic cells induce a T cell response against colon cancer in vitro and in vivo.
    Wu YG; Wu GZ; Wang L; Zhang YY; Li Z; Li DC
    Med Oncol; 2010 Sep; 27(3):736-42. PubMed ID: 19669608
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Potent in vivo anti-tumor activity of isolated CD62L(low) lymph node cells sensitized in vivo with tumor lysate-pulsed DC-based vaccines.
    Liu Z; Fan H; Wu Y; Chen B
    Cytotherapy; 2005; 7(4):353-62. PubMed ID: 16162457
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cancer immunotherapy using in vitro genetically modified targeted dendritic cells.
    Wei H; Wang H; Lu B; Li B; Hou S; Qian W; Fan K; Dai J; Zhao J; Guo Y
    Cancer Res; 2008 May; 68(10):3854-62. PubMed ID: 18483270
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Induction of cytotoxic T lymphocytes against human cancer cell lines using dendritic cell-tumor cell hybrids generated by a newly developed electrofusion technique.
    Imura K; Ueda Y; Hayashi T; Itoh T; Shimizu K; Tamai H; Yano Y; Naito K; Kohara J; Nakane K; Matsuura Y; Takeda A; Takeda T; Kawai K; Yamagishi H
    Int J Oncol; 2006 Sep; 29(3):531-9. PubMed ID: 16865268
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Combinational adenovirus-mediated gene therapy and dendritic cell vaccine in combating well-established tumors.
    Xia D; Moyana T; Xiang J
    Cell Res; 2006 Mar; 16(3):241-59. PubMed ID: 16541123
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Modification of dendritic cells with interferon-gamma-inducible protein-10 gene to enhance vaccine potency.
    Kang TH; Bae HC; Kim SH; Seo SH; Son SW; Choi EY; Seong SY; Kim TW
    J Gene Med; 2009 Oct; 11(10):889-98. PubMed ID: 19618483
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Constitutively active STAT5b induces cytokine-independent growth of the acute myeloid leukemia-derived MUTZ-3 cell line and accelerates its differentiation into mature dendritic cells.
    Bontkes HJ; Ruizendaal JJ; Kramer D; Santegoets SJ; Scheper RJ; de Gruijl TD; Meijer CJ; Hooijberg E
    J Immunother; 2006; 29(2):188-200. PubMed ID: 16531819
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Enhancement of immunologic tumor regression by intratumoral administration of dendritic cells in combination with cryoablative tumor pretreatment and Bacillus Calmette-Guerin cell wall skeleton stimulation.
    Udagawa M; Kudo-Saito C; Hasegawa G; Yano K; Yamamoto A; Yaguchi M; Toda M; Azuma I; Iwai T; Kawakami Y
    Clin Cancer Res; 2006 Dec; 12(24):7465-75. PubMed ID: 17189420
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Vaccination with recombinant adenoviruses and dendritic cells expressing prostate-specific antigens is effective in eliciting CTL and suppresses tumor growth in the experimental prostate cancer.
    Kim S; Lee JB; Lee GK; Chang J
    Prostate; 2009 Jun; 69(9):938-48. PubMed ID: 19267351
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Increased survival and decreased tumor size due to intratumoral injection of ethanol followed by administration of immature dendritic cells.
    Kumagi T; Akbar SM; Horiike N; Onji M
    Int J Oncol; 2003 Oct; 23(4):949-55. PubMed ID: 12963973
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Mutual helper effect in copulsing of dendritic cells with 2 antigens: a novel approach for improvement of dendritic-based vaccine efficacy against tumors and infectious diseases simultaneously.
    Shojaeian J; Jeddi-Tehrani M; Dokouhaki P; Mahmoudi AR; Ghods R; Bozorgmehr M; Nikoo S; Bayat AA; Akhondi MM; Ostadkarampour M; Rezania S; Zarnani AH
    J Immunother; 2009 May; 32(4):325-32. PubMed ID: 19342973
    [TBL] [Abstract][Full Text] [Related]  

  • 58. More efficient induction of HLA-A*0201-restricted and carcinoembryonic antigen (CEA)-specific CTL response by immunization with exosomes prepared from heat-stressed CEA-positive tumor cells.
    Dai S; Wan T; Wang B; Zhou X; Xiu F; Chen T; Wu Y; Cao X
    Clin Cancer Res; 2005 Oct; 11(20):7554-63. PubMed ID: 16243831
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Immunotherapy of intracranial G422 glioblastoma with dendritic cells pulsed with tumor extract or RNA.
    Zhang Z; Tang LL; Zhan RY; Tong Y; Yao HP; Du LA
    J Zhejiang Univ Sci; 2004 Oct; 5(10):1298-303. PubMed ID: 15362204
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Synergy between in situ cryoablation and TLR9 stimulation results in a highly effective in vivo dendritic cell vaccine.
    den Brok MH; Sutmuller RP; Nierkens S; Bennink EJ; Toonen LW; Figdor CG; Ruers TJ; Adema GJ
    Cancer Res; 2006 Jul; 66(14):7285-92. PubMed ID: 16849578
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.